S223: REAL-WORLD EARLY OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

• Caron Jacobson,
• Michael T. Hemmer,
• Zhen-Huan Hu,
• Matthew Frank,
• Leslie Popplewell,
• Nausheen Ahmed,
• Yi Lin,
• Timothy Best,
• Sara Beygi,
• Harry Miao,
• Christine Fu,
• Fang Sun,
• Hairong Xu,
• Marcelo Pasquini

Affiliations

Caron Jacobson

1 Dana-Farber Cancer Institute, Boston, United States

Michael T. Hemmer

2 Kite, a Gilead Company, Santa Monica, United States

Zhen-Huan Hu

2 Kite, a Gilead Company, Santa Monica, United States

Matthew Frank

3 Stanford University, Stanford, United States

Leslie Popplewell

4 City of Hope, Duarte, United States

Nausheen Ahmed

5 University of Kansas Medical Center, Kansas City, United States

Yi Lin

6 Mayo Clinic, Rochester, United States

Timothy Best

2 Kite, a Gilead Company, Santa Monica, United States

Sara Beygi

2 Kite, a Gilead Company, Santa Monica, United States

Harry Miao

2 Kite, a Gilead Company, Santa Monica, United States

Christine Fu

2 Kite, a Gilead Company, Santa Monica, United States

Fang Sun

2 Kite, a Gilead Company, Santa Monica, United States

Hairong Xu

2 Kite, a Gilead Company, Santa Monica, United States

Marcelo Pasquini

7 Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, United States